Carlsmed (NASDAQ: CARL) has emerged as a notable player in the “Surgical, Medical, and Dental Instruments and Supplies” industry, competing against 27 other public companies. Recent analyses reveal that while Carlsmed trails its peers in revenue, it surpasses them in earnings per share (EPS). The company is currently valued more affordably than its competitors, as it trades at a lower price-to-earnings ratio.
Profitability and Analyst Insights
Carlsmed is gaining attention for its potential growth. Analysts report a consensus price target of $21.33 for the company, indicating a substantial upside of 77.78%. This figure significantly exceeds the average potential upside of 52.07% for other companies within the same sector. This optimistic outlook suggests that analysts view Carlsmed as a more favorable investment compared to its peers.
Institutional ownership also highlights investor confidence, with approximately 19.3% of shares in the “Surgical, Medical, and Dental Instruments and Supplies” sector held by institutional investors. Carlsmed’s own institutional ownership stands at 19.5%, suggesting strong belief in its long-term growth potential.
Innovative Technology and Market Potential
Carlsmed is making waves with its innovative aprevo Technology Platform, which utilizes artificial intelligence (AI) to create personalized surgical solutions for spine surgery. The platform is designed to enhance clinical outcomes while reducing healthcare costs associated with spine procedures. By offering tailored surgical plans and interbody implants that accommodate each patient’s unique anatomical needs, Carlsmed aims to set a new standard for spine fusion surgery.
The platform is currently marketed for lumbar spine fusion, with plans to expand into cervical spine surgeries, expected to launch commercially in 2026. The Centers for Medicare and Medicaid Services (CMS) has proposed new reimbursement codes for custom-made fusion devices, which could provide up to $21,125 per cervical procedure, further boosting the market potential for Carlsmed’s offerings.
The total addressable market for the aprevo Technology Platform in the United States is estimated at around $13.4 billion, based on projected lumbar fusion surgeries. Carlsmed anticipates that its technology could significantly reduce the number of revision surgeries, which are costly and often exceed $100,000.
Clinical Evidence and Growth Trajectory
Carlsmed’s commitment to improving surgical outcomes is supported by a wealth of clinical data. The company has published seven peer-reviewed studies demonstrating the efficacy of its platform in achieving proper post-operative alignment and minimizing the need for revision surgeries. Interim data from the ongoing COMPASS Registry, which tracks outcomes for 338 patients, reveals a revision rate of only 1.5% among patients with adult spinal deformity (ASD).
The company continues to experience steady growth, with an increase in the number of surgeons utilizing the aprevo Technology Platform. As of March 31, 2025, 177 surgeons had completed procedures using the platform, a marked increase from 103 the previous year. This growth trend indicates a burgeoning acceptance and demand for Carlsmed’s innovative solutions.
Carlsmed’s approach combines direct sales efforts with independent agents, enhancing its reach within hospitals and surgical centers. The company is focused on expanding its commercial infrastructure, increasing its sales team, and fostering partnerships with top academic institutions to facilitate education and training in its technology.
In summary, Carlsmed stands out in the competitive landscape of surgical technology by leveraging AI to optimize spine surgery outcomes. With strong analyst support, a growing surgeon base, and a significant market opportunity, Carlsmed is well-positioned for continued growth and innovation in the healthcare sector.
